There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis
Food and Drug Administration findings during the approval process
Training for HR teams, managers, and leaders can further reinforce these standards
You should contact your GP or healthcare provider if: Night sweats are severe, persistent, or worsening over time You experience unintentional weight loss beyond what is expected from Mounjaro therapy Night sweats are accompanied by fever, chills, or signs of infection You notice fatigue, weakness, or unexplained changes in appetite There are symptoms suggestive of hypoglycaemia , such as confusion, tremor, palpitations, or waking feeling unwell You develop new or unusual symptoms such as lumps, persistent cough, or changes in bowel habits You experience severe, persistent abdominal pain radiating to the back (seek urgent medical attention as this could indicate pancreatitis) These features may indicate underlying conditions that require investigation, such as infections (including tuberculosis), hyperthyroidism, lymphoma, or other systemic illnesses
